欧洲临床试验发现 十六VO的心脏技术 将移植后的并发症 减少了44% 与基于冰层的保存相比 European clinical trial finds XVIVO's heart technology reduces post-transplant complications by 44% compared to ice-based preservation.
欧洲临床试验显示,XVIVO的心脏技术减少了移植后的严重并发症,与基于冰的保存相比,风险降低了44%。 European clinical trial shows XVIVO's heart technology reduces severe complications post-transplantation, with a 44% lower risk compared to ice-based preservation. 这项发表在"柳叶刀"杂志上的研究对比了8个欧洲国家的15个试验场所的204名患者. The study, published in The Lancet, compared 204 patients across 15 trial sites in eight European countries. 在临床心脏移植中,XVIVO的低温氧化输液 (HOPE) 心脏辅助输送装置提供了更安全,更有效的捐赠者心脏保存. XVIVO's Heart Assist Transport device with hypothermic oxygenated perfusion (HOPE) offers safer and more effective donor heart preservation in clinical heart transplantation.